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High telomerase activity and long telomeres in
advanced hepatocellular carcinomas with
poor prognosis
Bong-Kyeong Oh1,*, Haeryoung Kim2,*, Young Nyun Park3,4,5,6, Jeong Eun Yoo3,4,5,6, Jinsub Choi7,
Kyung-Sik Kim7, Jae Jung Lee3 and Chanil Park3,4
Telomerase reactivation and telomere maintenance are crucial in carcinogenesis and tumor progression. In this study, the
relationships between telomere parameters, chromosomal instability and clinicopathological features were evaluated
in hepatocellular carcinomas (HCCs). Telomere length (TL), telomerase activity (TA) and human telomerase reverse
transcriptase (hTERT) mRNA levels were measured in 49 hepatitis B virus (HBV)-related HCCs and corresponding
non-tumorous tissues. The results were compared with clinicopathological data, including differentiation, multipolar
mitosis (MM), anaphase bridge, immunohistochemical stain results for cytokeratin 19 (CK19) and patient outcome. TL
of HCCs ranged from 4.7 to 13.1 kb, and 44.4% of HCCs showed telomere lengthening. hTERT mRNA levels and TA were
closely related (P¼ 0.008), and were significantly higher in HCCs than non-tumorous tissues. TL was significantly higher
in HCCs with strong TA (P¼ 0.048), high hTERT mRNA levels (P¼ 0.001) and poor differentiation (P¼ 0.041). Frequent
MM was associated with poor differentiation (P¼ 0.007) and advanced stage (Po0.001). TA was positively correlated with
MM, anaphase bridges and advanced stage (P¼ 0.019, P¼ 0.017 and P¼ 0.029). Thirteen (28.3%) HCCs were CK19þ and
demonstrated longer telomeres than CK19 HCCs (P¼ 0.046). Overall survival was poor in HCCs with MM 40.4 per field
(P¼ 0.016), high TA (P¼ 0.009) and high TL ratio (HCC/non-HCC) 40.8 (P¼ 0.044). Our results show that long telomeres,
high TA and high mitotic instability are poor prognostic markers for HBV-related HCCs and their close association
suggests that telomere maintenance may be important for the progression of HCCs with high chromosomal instability
to more aggressive ones.
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The telomere, a distinctive DNAprotein structure at the end
of chromosomes, stabilizes the natural end of the chromo-
some and protects against end-to-end fusion.1,2 Telomerase is
a ribonucleoprotein complex composed of two key compo-
nents: a catalytic component (human telomerase reverse
transcriptase, hTERT) and an RNA template. hTERT is a
reverse transcriptase that synthesizes telomere repeats from
the RNA template, and it is a limiting component in telo-
merase activity (TA).3,4 During the early stages of carcino-
genesis, cells undergo extensive proliferation until telomere
length (TL) becomes critically shortened. Cells with dys-
functional telomeres gain further chromosomal instability
through breakage–fusion–bridge cycles during replication,
which have a catastrophic effect on cells. However, telomerase
reactivation can stabilize the chromosome ends and produce
aberrant, yet stable chromosomes; these cells then gain in-
finite life.5,6 A current hypothesis is that telomere dysfunction
leads to mitotic disturbances, giving rise to a high rate of
chromatin bridges at anaphase and multipolar mitosis
(MM).7 Tumors with high rates of anaphase bridging (such
as ovarian, head and neck tumors) are characterized by a
multimodal distribution of genomic imbalances, consistent
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with a dramatically increased rate of chromosomal re-
arrangement.8,9
Hepatocellular carcinoma (HCC) is the seventh most
common cancer worldwide, accounting for the highest
number of adult malignancies in areas endemic for hepatitis
B virus (HBV). Telomere shortening is an early event in
multistep hepatocarcinogenesis, occurring in preneoplastic
lesions of dysplastic nodules10,11 and shortened telomeres
have been reported to induce chromosomal instability in
hepatocytes, especially important in HBV-related hepato-
carcinogenesis.12,13 However, the roles of telomere dysfunc-
tion and telomerase parameters in the progression of human
HCCs have not been systematically analyzed.
In this study, the relationships between TL, TA, hTERT
mRNA and pathological parameters (including differentia-
tion, MM and anaphase bridge) and patient outcome were
evaluated in HCCs and corresponding non-tumorous livers
to clarify their roles in the progression of HCCs.
MATERIALS AND METHODS
Materials and Histopathological Examination
Forty-nine HCCs and their corresponding non-tumorous
livers were retrieved from the archival files of Severance
Hospital, Yonsei University College of Medicine. This study
was approved by the Institutional Review Board of Severance
Hospital, Yonsei University College of Medicine, and the
specimens were supported by the Liver Cancer Specimen
Bank from the National Research Resource Bank Program of
the Korea Science and Engineering Foundation in the Min-
istry of Science and Technology. The tissues sampled from
resected liver specimens were snap-frozen in liquid nitrogen
and stored at 701C. The patient population consisted of
36 males and 13 females, and their ages ranged from 35 to
69 years (53.7±9.18 years, mean±s.d.). All of the non-
tumorous liver samples showed HBV-associated chronic
hepatitis or cirrhosis. Representative sections were submitted
for routine histological examination.
Hematoxylin and eosin (H&E)-stained tissue sections were
examined under a light microscope using  400 magnifica-
tion for mitosis, MM and anaphase bridges. At least 10 high-
power fields (HPFs) were reviewed. Metaphase and anaphase
cells with chromosomes showing three or more spindle poles
were classified as multipolar. Anaphase bridging was defined
as an anaphase event in which more than two-thirds of
the distance between anaphase poles was spanned by the
bridging chromosome,14 to avoid the counting of lagging
chromosomes.
Analysis of TL
Analysis was performed as described by a previous report.10
TL was measured from 2mg HinfI-digested DNA. Hy-
bridization was carried out with a 30-end DIG-labeled
d(TTAGGG)4 (Roche Molecular Biochemicals, Mannheim,
Germany) at 371C overnight. TL (telomere repeat frequency)
was calculated using a previously described method;15 mean
TL was obtained from two or three replicate experiments.
Telomeric Repeat Amplification Protocol Assay
TA was examined with a telomeric repeat amplification
protocol (TRAP) using a TRAPezes ELISA telomerase
detection kit (Intergen, NY, USA).10 All samples were assayed
with 0.2 mg lysate, providing activity in the linear range.
Assays were duplicated; the mean values were taken as the TA
of the samples. The activity was semiquantified by ELISA, as
recommended by the manufacturer: high activity (þ þ þ ):
Z1.5; moderate activity (þ þ ): 0.5–1.5; low activity (þ ):
o0.5.
Real-Time Quantitative RT-PCR for hTERT mRNA
The analysis for hTERT mRNA was performed using real-
time quantitative RT-PCR, based on TaqMan methodology
and using an ABI PRISM 7700 sequence detection system
(Perkin-Elmer, CA, USA). A standard RNA, prepared by
in vitro run-off transcription with T7 RNA polymerase, was
used for a standard curve. This was prepared from 5 to 6
dilutions of the standard hTERT RNA (3 101 to 3 105
copies) and GAPDH RNA (3 102 to 3 106 copies). PCR
and thermal cycling were carried out as described in a pre-
vious report.16 Sequences of the hTERT primers and probe
were as follows: hTERT-F, 50-CACGCGAAAACCTTCCTCA-
30; hTERT-R, 50-CAAGTTCACCACGCAGCC-30, and the
probe, 50-(FAM)-CTCAGGGACACCTCGGACCAGGGT-
(TAMRA)-30. Sequences of the GAPDH primers and probes
were as follows: GAPDH-F, 50-CCTCTGACTTCAACAGCG
ACAC-30; GAPDH-R, 50-GTGGTCGTTGAGGGCAATG-30;
and the probe, 50-(FAM)-CACTCCTCCACCTTTGACGCT
GGG-(TAMRA)-30.
Immunohistochemistry for Cytokeratin 19
Paraffin sections were deparaffinized with xylene and rehy-
drated with graded alcohol. After washing in distilled water
the sections were immersed in 3% hydrogen peroxide to
block endogenous peroxidases. Antigen retrieval was per-
formed by boiling the sections in 100 mM sodium citrate (pH
6.0) for 15 min in a microwave oven. Monoclonal primary
antibody (cytokeratin 19, DAKO, Glostrup, Denmark) at a
1:50 dilution was applied for 30 min at room temperature
followed by washing in PBS. Incubation with the secondary
antibody was carried out using the DAKO EnVision Rabbit/
Mouse kit for 30 min at room temperature, developed with
diaminobenzidine (DAKO), and counterstained with hema-
toxylin. Strong cytoplasmic staining in at least more than 5%
of the tumor cells classified HCCs as CK19þ .
Statistical Analysis
Statistical analysis was performed using the SPSS software
package, version 12.0 (SPSS Inc., Chicago, IL, USA). Differ-
ences in telomere parameters among various groups of
patients discriminated for histopathologic parameters and
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CK19 expression status were analyzed by the Kruskal–Wallis
and Mann–Whitney two-sample tests. Correlations between
histopathological parameters and telomere parameters were
analyzed by the Spearman’s correlation test. The Kaplan–
Meier method was used for analysis of overall survival. A P-
value of less than 0.05 was considered statistically significant.
RESULTS
Histopathological Features and Mitotic Instability in
Hepatocarcinogenesis
The HCCs ranged from 1 to 18 cm in size (5.7±4.1 cm).
According to Edmondson’s grading scores, the differentiation
of HCCs was as follows: grade I in 2 cases, grade II in 24
cases, grade III in 22 cases and grade IV in 1 case. The TNM
stages of the HCCs according to the 2002 American Joint
Committee on Cancer (AJCC)/International Union Against
Cancer (UICC) system were as follows: stage I in 17 cases,
stage II in 16 cases, stage III in 10 cases (stage IIIA in 8 cases,
stage IIIB in 1 case and stage IIIC in 1 case) and stage IV in 6
cases. The TNM stage and histologic grade of the HCCs
were significantly correlated (P¼ 0.037). The mitotic count
of HCCs ranged from 0 to 17 mitotic figures per HPF
(3.09–3.22), and a significant positive correlation was shown
between mitotic count and differentiation (P¼ 0.033) and
TNM stage (Po0.001). Clinicopathological characteristics
are summarized in Table 1.
Anaphase bridges were found in 15 HCCs (30.6%;
0.03±0.06 per HPF) (Figure 1a). MM were found in 35 cases
(71.4%), and the number of MM per HPF ranged from 0 to
3.9 (0.58±0.917) (Figure 1b). Anaphase bridges and MM
were significantly positively correlated (P¼ 0.001). MM were
more frequent in poorly differentiated HCCs (P¼ 0.007) and
in HCCs of advanced stage (Po0.001), while anaphase
bridges were not significantly correlated with histological
parameters.
Relationships between Telomere Parameters in
Hepatocarcinogenesis
TLs were measured in 45 HCCs and compared with their
adjacent non-neoplastic tissues (Table 1). TLs ranged from
4.7 to 13.1 kb in HCCs and from 6.3 to 12.6 kb in non-HCCs
and the TL ratios of HCCs to non-tumorous livers (TLR)
ranged from 0.61 to 1.54 (0.97±0.204). Twenty-five HCCs
(55.6%) demonstrated shorter telomeres than their adjacent
non-tumorous livers (7.2±1.59 and 8.7±1.69 kb, respec-
tively), while the remaining 20 HCCs (44.4%) appeared to
have longer telomeres than non-neoplastic tissues (9.4±1.23
and 8.3±0.94 kb, respectively).
TA was measured in 40 HCCs and their adjacent non-
neoplastic tissues (Table 1) and the data were partly reported
earlier.16 TL in HCCs with high TA were significantly higher
than in those with low or moderate TA (8.8±2.10 and
7.7±1.62, respectively; P¼ 0.048) (Figure 2). There was also
a significant positive correlation between TLR and TA
(P¼ 0.038).
hTERT mRNA levels were determined in the same tissues
used for the determination of TA, and ranged from 15 to
28115 (1477.5±4483.30) in HCCs and from 0 to 166
(38.6±49.39) in non-neoplastic tissues (Table 1). In all cases,
the HCCs demonstrated higher levels of hTERT mRNA than
adjacent non-tumorous livers. A significant positive correla-
tion between hTERT mRNA level and TA was found in
the HCCs (P¼ 0.008). In addition, higher hTERT mRNA
levels were significantly associated with longer telomeres
(P¼ 0.001) (Figure 3a) and higher TLR (P¼ 0.034).
Relationship between Telomere Parameters,
Histopathological Parameters and Mitotic Instability
TLs were longer in HCCs with poorer differentiation
(P¼ 0.041; 7.7±1.80 kb in grade I and II HCCs vs
8.7±1.66 kb in grade III and IV HCCs). TL showed positive
correlations with mitotic activity (P¼ 0.002).
High TA was significantly associated with advanced tumor
stage, high mitotic rates, frequent MM and anaphase bridges
(P¼ 0.029, P¼ 0.032, P¼ 0.019 and P¼ 0.017, respectively).
hTERT mRNA levels were positively correlated with advanced
tumor stage, mitotic count and MM (P¼ 0.012, Po0.001
and P¼ 0.011, respectively) (Figure 3b and c), but no
significant relations were seen between hTERT mRNA levels
and anaphase bridges.
Relationships between CK19 Positivity, Telomere
Parameters and Mitotic Instability
Immunohistochemical stain for the biliary epithelial cell
marker CK19 was performed in 46 HCCs, and 13 (28.3%)
cases showed strong cytoplasmic staining for CK19 in more
than 5% of the tumor cells (Table 1). In fact, 5 of the 13
CK19þ cases focally demonstrated histological features of
progenitor cell or biliary differentiation: areas of relatively
small and monomorphous tumor cells with scant cytoplasm,
partly arranged in tubule-like structures. Interestingly,
CK19þ HCCs demonstrated significantly longer telomeres
than those with CK19 negativity (8.97±1.34 vs 7.89±
1.87 kb; P¼ 0.046) (Figure 4) and showed increased hTERT
mRNA levels compared to CK19 HCCs (although not
statistically significant).
Effects of Telomere Parameters and Mitotic Instability
on Prognosis
Follow-up visits were possible in 45 of the 49 cases, with the
follow-up period ranging from 4 to 42 months (mean¼ 22
months). Local recurrences were seen in 19 of the 49 patients
(38.8%) after a mean of 14 months of disease-free survival.
Eleven patients (24.4%) died of hepatic failure or metastasis 4
to 24 months following operation (Table 1).
A poorer prognosis was seen in HCCs with an MM Z0.4
per HPF (P¼ 0.016). Overall survival was poor when the
TLR was greater than 0.8 (P¼ 0.044) and in cases with high
TA (P¼ 0.009) (Figure 5a–c). When combining TLR with
TA, three prognostic groups could be defined (Figure 5d).
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Table 1 Clinicopathological characteristics and telomere parameters of the observed hepatocellular carcinoma cases
Case Sex Age Size (cm) Stage Grade M/f MM/f AB/f CK19 TA(T) TRF(T) TL ratio hTERT(T) F/U (*: death)
1 F 54 4.6 1 2 0.29 0.04 0.00  +++ 4.7 0.62 123 34
2 M 41 3.0 1 2 0.81 0.23 0.04  + 5.1 0.61 NA 32
3 M 65 3.0 1 2 0.05 0.05 0.00  ++ 5.1 0.61 234 29
4 M 54 4.0 2 3 0.00 0.00 0.00  + 5.1 0.80 57 21*
5 M 61 3.0 1 1 0.14 0.00 0.00  + 5.4 0.72 85 28
6 F 65 9.0 1 2 0.14 0.00 0.00 + ++ 6.0 0.68 NA 28
7 F 51 3.0 1 1 0.71 0.07 0.07  ++ 6.1 0.87 238 30
8 M 59 11.0 4 2 2.17 0.06 0.00  +++ 6.2 0.91 811 8*
9 M 40 11.0 4 2 2.78 0.61 0.00  +++ 6.4 0.85 313 6*
10 M 42 2.8 2 3 1.10 0.05 0.00  ++ 6.6 0.93 223 42
11 F 35 3.5 1 2 0.95 0.00 0.00  + 6.9 0.96 15 29
12 M 47 4.5 2 3 2.94 0.71 0.00  ++ 7.0 0.80 495 21*
13 M 56 16.0 3A 3 0.85 0.20 0.00  + 7.1 0.92 231 20*
14 M 40 2.5 2 2 NA NA NA  + 7.3 0.79 554 30
15 M 56 2.5 1 2 3.00 0.06 0.06  NA 7.6 0.99 NA NA
16 M 62 3.0 1 3 5.00 1.40 0.00 + ++ 7.6 1.03 417 15
17 M 50 2.2 2 2 4.53 0.12 0.00 + ++ 7.7 1.22 1220 32
18 F 65 3.5 1 2 1.52 0.14 0.05  ++ 8.0 0.83 120 39
19 M 61 5.0 2 2 1.89 0.00 0.00  + 8.0 0.95 352 32
20 M 39 7.5 3A 3 8.55 3.90 0.09  + 8.1 0.92 153 17
21 M 50 10.4 3C 3 5.13 1.00 0.13  +++ 8.1 1.01 1639 NA
22 F 62 7.0 4 2 4.72 1.33 0.22  +++ 8.5 0.93 115 10*
23 F 54 5.5 2 3 0.44 0.13 0.00 + ++ 8.5 0.98 190 40
24 M 56 2.3 1 3 NA NA NA + NA 8.5 0.73 217 40
25 M 60 3.5 2 2 0.69 0.00 0.00  ++ 8.6 1.13 242 15*
26 M 43 15.0 4 3 8.00 2.18 0.06 + +++ 8.8 1.10 28115 4*
27 M 58 3.0 1 3 0.22 0.00 0.00  + 8.8 1.02 222 28
28 F 67 6.5 2 3 1.75 0.00 0.00  + 8.8 1.13 197 12
29 M 51 3.5 1 2 0.53 0.00 0.00  ++ 8.9 1.06 339 17
30 F 49 5.6 3A 3 16.56 3.78 0.00 + ++ 8.9 1.00 202 14
31 M 48 4.2 3A 3 6.42 0.42 0.33  +++ 8.9 0.84 1062 8
32 M 43 3.2 3A 2 9.67 2.44 0.06  +++ 9.1 1.11 2156 NA
33 F 60 3.0 4 2 3.67 0.58 0.00 + +++ 9.4 1.15 1695 22*
34 M 59 3.2 2 2 2.23 0.38 0.00  NA 9.4 1.27 NA NA
35 M 45 3.5 2 3 3.09 0.45 0.09  +++ 9.5 1.13 3993 15
36 M 54 6.0 3A 3 1.92 0.00 0.00 + + 9.5 1.02 NA 12
37 M 64 2.7 1 2 2.36 0.00 0.00  NA 9.7 0.90 487 12
38 M 43 4.5 3A 3 6.91 1.36 0.00  ++ 9.8 0.80 3354 17
39 M 55 4.0 2 3 4.06 0.88 0.19  +++ 10.1 1.01 262 12
40 F 53 17.0 2 2 0.92 0.00 0.00 + NA 10.2 1.38 NA 17
41 M 63 2.5 2 3 4.20 0.60 0.00 + + 10.3 0.82 1982 20
42 M 62 5.0 1 2 0.09 0.00 0.00  +++ 10.4 1.37 134 15
43 F 52 3.6 2 2 4.09 0.91 0.00 + ++ 10.5 1.02 587 17
44 M 55 8.5 3B 3 NA NA NA + +++ 10.7 1.19 2625 37
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Group 1 comprised HCCs with shortened telomeres (TLR
o0.8) regardless of TA and demonstrated a survival rate of
100%. Group 2 consisted of HCCs with TLR Z0.8 and low/
moderate TA (survival rate: 80%), and group 3 HCCs were
those with TLR Z0.8 and high TA (survival rate: 54.5%).
The differences in survival between the three groups were
statistically significant (group 1 vs group 3: P¼ 0.037, group
2 vs group 3: P¼ 0.043), demonstrating that the combination
of maintained or lengthened telomeres and high TA serve as
ominous prognostic factors in HCCs. CK19 expression status
of HCCs demonstrated no significant influence on patient
survival.
DISCUSSION
Telomere dysfunction plays an important role in carcino-
genesis by the induction of chromosomal instability through
the breakage–fusion–bridge cycle of affected cells, and telo-
mere shortening has been shown to be crucial in the initia-
tion of carcinogenesis.17,18 Previous studies on dysplastic
nodules and dysplastic foci of the liver demonstrated
that telomere shortening occurs in the early stages of
Table 1 Continued
Case Sex Age Size (cm) Stage Grade M/f MM/f AB/f CK19 TA(T) TRF(T) TL ratio hTERT(T) F/U (*: death)
45 M 67 3.5 1 3 7.15 0.08 0.00  +++ 13.1 1.54 2168 28
46 M 66 10.0 3A 4 1.97 1.31 0.06 NA NA NA NA NA 7*
47 M 36 11.0 2 3 1.22 0.78 0.04  NA NA NA NA 41
48 M 69 18.0 4 2 5.16 0.21 0.06 NA NA NA NA NA 24*
49 F 44 1.0 1 2 1.57 0.00 0.00 NA NA NA NA NA 30
AB/f, anaphase bridge per high-power field; F/U, follow-up (months); M/f, mitosis per high-power field; MM/f, multipolar mitosis per high-power field; NA, data not
available; TA(T), telomerase activity (tumor), TL ratio, telomere length ratio; TRF(T), telomere repeat frequency (tumor).
Figure 1 Hepatocellular carcinoma showing anaphase bridging (arrow)
(a) and multipolar mitosis (arrows) (b) (hematoxylin and eosin, original
magnification  400).
Figure 2 Telomere length according to telomerase activity (TA) in
hepatocellular carcinomas (HCCs) (mean±s.d.). Telomere length is
significantly higher in HCCs with strong TA than HCCs with low or
moderate TA (Po0.05) (TRF(T), telomere repeat frequency of tumor).
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hepatocarcinogenesis,10,11,19 again providing evidence for the
importance of telomere dysfunction in cancer initiation.
However, not all preneoplastic lesions are considered to be
capable of fully advancing to cancer. Only those cells that find
a way to maintain their telomeres, thus allowing unlimited
cell division and some degree of chromosomal instability, will
be able to progress to more advanced malignant tumors.
Therefore, while telomere shortening and chromosomal in-
stability take place in the earlier stages of carcinogenesis,
cancer progression is associated with telomere maintenance.
In this study, we analyzed TLs of HBV-related HCCs, and
found that although just over a half (55.6%) of our HCCs
had shorter telomeres compared to non-neoplastic livers, a
substantial percentage (44.4%) demonstrated unchanged or
even increased TLs. In addition, TL was positively correlated
with poorer differentiation. Nakajima et al20 reported that
HCCs of less than 5 cm showed a negative correlation be-
tween TL and tumor size, that is, TLs decreased with in-
creasing tumor size, whereas tumors larger than 5 cm showed
size-independent TLs and were associated with highly ma-
lignant clinicopathological features. As TLs of HCCs and
corresponding non-neoplastic livers vary for each individual,
the TLR was calculated in each case as in previous studies21,22
to analyze the alteration status of TL relative to the paired
non-tumorous tissue. Interestingly, we found that the group
of patients with TLR Z0.8 showed a poorer overall survival,
implying that maintenance or elongation of telomeres in
HCCs may serve as a poor prognostic factor. The association
of long telomeres with advanced stages and poorer survival
has also been recently reported in other tumors including
colorectal cancers and head and neck tumors.21–26
Figure 3 The relationships between hTERT mRNA levels and telomere
length (a), mitosis (b) and multipolar mitosis (c) (hTERT(T), hTERT mRNA
levels of the tumor; M/f, mitotic figures per  400 field; MM/f, multipolar
mitosis per  400 field). Significant positive correlations are seen between
hTERT mRNA levels and telomere length (P¼ 0.001), mitosis (Po0.001) and
multipolar mitosis (P¼ 0.011).
Figure 4 Telomere length according cytokeratin 19 expression status in
HCCs (mean±s.d.). Telomeres of CK19þ HCCs were significantly longer
than those of CK19 tumors (Po0.05).
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In this study, all HCCs demonstrated higher hTERT
mRNA levels than their corresponding non-tumorous tissues,
and the positive correlation between hTERT level and TA in
our study supports previous studies which showed that
hTERT is a key regulator of TA in hepatocarcinogenesis.27–30
In addition, hTERT mRNA levels were positively correlated
with TLs and HCCs with high TA showed minimal short-
ening or even lengthening of telomeres, suggesting that telo-
merase may play a significant role in telomere maintenance
or lengthening during HCC progression. Furthermore,
advanced tumor stage and poorer overall survival were seen
in HCCs with strong TA supporting previous reports that
Figure 5 Kaplan–Meier curve for overall survival of HCC patients according to telomerase activity (TA) (a), telomere length ratio (TL ratio) of the HCC to the
non-tumorous livers (b), and multipolar mitosis (MM) count (c). Three prognostic groups could be defined after combination of TL ratio with TA (d) group 1,
TL ratio o0.8 regardless of TA status; group 2, TL ratio Z0.8 and low/moderate TA; group 3, TL ratio Z0.8 and high TA.
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showed HCCs with higher TA were more aggressive with
frequent recurrence after operation.31–33 In our study, the
difference in overall survival according to hTERT mRNA
levels failed to reach statistical significance, unlike previous
studies which showed that high hTERT expression was as-
sociated with a poorer prognosis in colorectal carcinomas
and ependymomas.34,35 However, we found that high hTERT
mRNA levels were significantly correlated with more
advanced tumor stage.
Chromosomal instability has been reported to play an
important role in the pathways of HBV-related hepatocarci-
nogenesis and in HCCs associated with poor differentiation
or poor prognosis.12,13 In this study, MM and anaphase
bridges were demonstrated in 71.4 and 30.6% of HBV-related
HCCs, respectively, and the two features were significantly
positively correlated. MM were more prevalent in poorly
differentiated HCCs and in those with advanced stage, and
HCCs with MM Z0.4 per HPF showed a poor overall sur-
vival in this study. To some extent, these results are consistent
with a previous report which demonstrated a close correla-
tion between the morphological dedifferentiation of HCCs
and an increase in chromosomal heterogeneity.36
In an animal study of successive generations of telomerase-
deficient mice, short dysfunctional telomere was reported to
be associated with a significant increase in the number of
early neoplastic lesions and a reciprocal decline in the
occurrence of high-grade malignancies.37 Similarly, hTERT-
mediated telomere stabilization is suggested to be critical for
the progression and prognosis of colorectal cancers.23 Lechel
et al38 demonstrated in their study of p53-mutant mice that
telomerase is a critical component for in vivo progression of
p53-mutant HCC with short telomeres in chronically da-
maged liver—telomerase limits the accumulation of telomere
dysfunction and chromosomal instability—and, therefore,
telomerase deletion limits the progression of p53-mutant
HCC with short telomeres. In our HCCs, those with chro-
mosomal instability (ie frequent MM and anaphase bridges)
showed significantly higher TA and hTERT mRNA levels,
again implying that these genetically instable tumors require
telomerase to prevent complete genomic deterioration and to
progress to more aggressive and advanced HCCs.
The concept of stem cell carcinogenesis has received a lot
of attention lately. Most direct evidence for the hypothesis of
cancer stem cells has come from studies on hematologic
malignancies. Shortening of telomeres has been shown in
lymphoid and myeloid leukemias suggesting that telomere
loss may contribute to cancer stem cell initiation; however,
cancer stem cells may acquire immortality by mutational
events in telomere-lengthening mechanisms such as telo-
merase activation, resulting in maintenance of TL, disease
progression, poor prognosis and increased risk of recurrence
in treated patients.39–41 Stem cells have also been implicated
in hepatocarcinogenesis; several studies have demonstrated
that as much as 28–50% of human HCCs express markers of
progenitor/biliary cells such as CK7, CK19 and OV6, and also
markers of hematopoietic stem cells such as c-kit and
CD34.42–44 These HCCs have been characterized by an im-
mature phenotype intermediate between biliary epithelial
cells and hepatocytes, and CK19 expression in HCC has been
associated with a worse prognosis.45–48 It is worth noting
from our study that telomeres of CK19þ HCCs were sig-
nificantly longer than those that were CK19, which could
support previous reports that HCCs with progenitor cell
features have a poor prognosis. However, no definite asso-
ciation between CK19 expression status and prognosis was
found in our study, probably attributed to the paucity of
CK19þ cases. Therefore, a more extensive study will be
necessary for a further understanding of the relationship
between hepatic stem cell carcinogenesis and telomere
dynamics.
In conclusion, TL, TA and mitotic instability are useful
prognostic markers for HBV-related HCCs. The close
association between TL, TA, mitotic instability and poor
prognosis suggests that maintenance of telomere may be
important for the progression of HCCs with high chromo-
somal instability to more aggressive ones. Telomerase in-
hibition and telomere regulation could be a possible target in
the treatment of both early and advanced HCCs.
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